Cancer

Major step forward as bladder cancer treatment approved in England

The National Institute for Health and Care Excellence estimates that more than 1,200 people each year in England could benefit from the enfortumab vedotin and pembrolizumab combination therapy.…

Health news round-up: AI, health inequalities and GLP-1 drugs

Senior clinical reporter Joanna Robertson shares some important developments in health news.…

Patients with head and neck cancer to be fast-tracked into NHS vaccine trial

The investigational mRNA cancer vaccine will be trialled across 15 NHS hospitals over 12 months, the third cancer vaccine trial to be run through the NHS Cancer Vaccine Launch Pad.…

Immunotherapy plus chemotherapy approved for endometrial cancer

Immunotherapy drug pembrolizumab (Keytruda: Merck Sharp and Dohme) could benefit 2,100 people with advanced womb cancer.…

Pharmacy at the frontline of tackling healthcare inequalities

This month’s column from the RPS chief scientist’s office looks at highlights from recent pharmacy practice research through the lens of Core20PLUS5.…

NICE approves expanded access to early breast cancer treatment

The National Institute for Health and Care Excellence estimates that its updated guidance will make ribociclib available to a further 5,700 patients.…

Pharmacies to trial test for risk of oesophageal cancer

NHS England said that the “heartburn health check” could help transfer care from hospitals to the community, as part of the NHS ten-year health plan.…

NICE recommends ‘breakthrough’ therapy for blood cancer

Belantamab mafodotin combination therapy is a second-line treatment option for multiple myeloma that could benefit around 1,500 people.…

Supporting pharmacists in improving the care delivered for people with cancer

The Pharmaceutical Journal has launched a cancer ‘hub page’ and educational resources on blood cancer as part of continued partnership with BeiGene.…

Promotional content

NICE reverses draft guidance to recommend targeted therapy for patients with advanced bowel cancer

The National Institute for Health and Care Excellence said the treatment should be available on the NHS after the manufacturer provided additional clinical evidence.…